The CAGT platform is designed to enable efficient delivery of high concentrations of an anti-cancer drug selectively to the cancer cells while sparing healthy tissue. Preclinical animal models of brain cancer show that this targeted cancer killing approach is well tolerated and can result in tumor destruction and prolonged survival in nearly all rodent animals treated. Based on these data we believe Tocagen’s CAGT technology platform may be used for the development of treatments for multiple tumor types and now may be able to fulfill the promise of gene transfer as a treatment for cancer.
